bioRxivMicrobiology
Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response
L. Shalamova, U. Felgenhauer, A. R. Schaubmar, K. Buettner, M. Widera, S. Ciesek, F. Weber
Abstract
The new variant of concern (VOC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Omicron (B.1.1.529), is genetically very different from other VOCs. We compared Omicron with the preceding VOC Delta (B.1.617.2) and the wildtype strain (B.1) with respect to their interactions with the antiviral type I interferon (IFN-alpha/beta) response in infected cells. Our data indicate that Omicron has gained an elevated capability to suppress IFN-beta induction upon infection and to better withstand the antiviral state imposed by exogenously added IFN-alpha.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
D. Bojkova, T. Rothenburger, … J. Cinatl·bioRxiv·Jan 20, 2022
- The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells
R. Nchioua, A. Schundner, … K. Sparrer·bioRxiv·Nov 16, 2021
- Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates
D. Bojkova, M. Widera, … J. N. Cinatl·bioRxiv·Jan 3, 2022
- Interferon Resistance of Emerging SARS-CoV-2 Variants
K. Guo, B. S. Barrett, … M. L. Santiago·bioRxiv·Mar 20, 2021
- Nasally-delivered interferon-{lambda} protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including Omicron
Z. Chong, C. E. Karl, … M. S. Diamond·bioRxiv·Jan 21, 2022
- Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
D. Bojkova, R. Stack, … J. Cinatl·bioRxiv·Jul 22, 2022